Form 4: Aprea Therapeutics CEO Oren Gilad Increases Stake in Company

Aprea Therapeutics' CEO, Oren Gilad, recently acquired additional shares of the company's common stock through open market purchases.

Summary

• Oren Gilad, the President and CEO of Aprea Therapeutics, has reported changes in his beneficial ownership of the company's stock.
• On April 3, 2025, Gilad purchased 3,003 shares of common stock at $1.87 per share and 2,497 shares at $1.80 per share.
• Following these transactions, Gilad directly owns 345,620 shares of Aprea Therapeutics.
• He also indirectly owns 1,200 shares through his daughter and 600 shares through his son.
• Gilad disclaims beneficial ownership of the shares held by his children.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is generally seen as a positive sign, but it's a relatively small transaction and doesn't provide definitive insight into the company's overall health.

Positives

• The CEO's purchase of shares could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Insider trading activity is closely monitored by regulators and investors as it can provide insights into a company's performance and future prospects. Form 4 filings are a routine part of this monitoring process.

Stakeholder Impact

• Shareholders may view the CEO's stock purchase as a positive signal.

Key Dates

Keywords

Aprea Therapeutics, Insider Trading, Beneficial Ownership, Form 4, Stock Purchase, Oren Gilad, APRE